Review

The case for low carbohydrate diets in diabetes management
Surender K Arora and Samy I McFarlane*

Address: Division of Endocrinology, Diabetes and Hypertension, SUNY Downstate Medical Center, and Kings County Hospital Center, Brooklyn, NY 11203 NY 11203, USA

Email: Surender K Arora - surenderkarora@yahoo.com; Samy I McFarlane* - Samy.McFarlane@downstate.edu
* Corresponding author

Abstract

A low fat, high carbohydrate diet in combination with regular exercise is the traditional recommendation for treating diabetes. Compliance with these lifestyle modifications is less than satisfactory, however, and a high carbohydrate diet raises postprandial plasma glucose and insulin secretion, thereby increasing risk of CVD, hypertension, dyslipidemia, obesity and diabetes. Moreover, the current epidemic of diabetes and obesity has been, over the past three decades, accompanied by a significant decrease in fat consumption and an increase in carbohydrate consumption. This apparent failure of the traditional diet, from a public health point of view, indicates that alternative dietary approaches are needed. Because carbohydrate is the major secretagogue of insulin, some form of carbohydrate restriction is a prima facie candidate for dietary control of diabetes. Evidence from various randomized controlled trials in recent years has convinced us that such diets are safe and effective, at least in short-term. These data show low carbohydrate diets to be comparable or better than traditional low fat high carbohydrate diets for weight reduction, improvement in the dyslipidemia of diabetes and metabolic syndrome as well as control of blood pressure, postprandial glycemia and insulin secretion. Furthermore, the ability of low carbohydrate diets to reduce triglycerides and to increase HDL is of particular importance. Resistance to such strategies has been due, in part, to equating it with the popular Atkins diet. However, there are many variations and room for individual physician planning. Some form of low carbohydrate diet, in combination with exercise, is a viable option for patients with diabetes. However, the extreme reduction of carbohydrate of popular diets (<30 g/day) cannot be recommended for a diabetic population at this time without further study. On the other hand, the dire objections continually raised in the literature appear to have very little scientific basis. Whereas it is traditional to say that more work needs to be done, the same is true of the assumed standard low fat diets which have an ambiguous record at best. We see current trends in the national dietary recommendations as a positive sign and an appropriate move in the right direction.

The case for low carbohydrate diets in diabetes management

The epidemic of obesity and diabetes in our society over the past three decades has been accompanied by a decline in fat consumption and an apparent attempt to adopt the traditionally recommended low fat diet [1,2]. According to the USDA Continuing Survey of Food Intakes by Individuals (CSFII) [2], the absolute amount of fat and saturated fat consumed has decreased during the obesity epidemic although there is slight increase for women...
from 1994 to 1995. This apparent failure of low fat diets in curbing the obesity pandemic calls into question the effectiveness and long-term usefulness of such dietary recommendation and has led to renewed interest in alternative dietary interventions, notably those recommending reduced carbohydrate intake. Low fat diets are generally associated with high carbohydrate intake which in turn is associated with several metabolic abnormalities [3,4]. These metabolic abnormalities are more pronounced in the diabetic population, leading to worsening glycemic control, dyslipidemia and increased inflammation to name a few. In this review, we discuss the current evidence for a low carbohydrate diet versus a low fat diet in the management of people with diabetes, highlighting the potential role of low carbohydrate diet in ameliorating various metabolic abnormalities associated with diabetes.

**Carbohydrate restriction**

It is important to understand that there is no clear cut definition of a low carbohydrate diet in the literature. Various popular versions recommend carbohydrates intake < 20% of caloric intake with absolute amounts < 50–60 gm/day, sometime as low as ≤ 20–30 gm/day at least for short periods. We distinguish between moderate but significant reduction in carbohydrates (LoCHO diet) and very low carbohydrate ketogenic diets (VLCKD) with extreme reductions (< 20 or 30 g/day) as in the early phase of the various popular diets [5-7]. The caloric deficit due to carbohydrate restriction may be balanced with increased intake of proteins and fats although the distribution is not always clear in the application of popular diets and, in at least two studies, no increase in dietary intake of proteins or fats was observed presumably due to effect of LoCHO diet on appetite and satiety [9,12] It is interesting that despite advocating *ad libitum* fat and protein intake, a LoCHO diet may be hypocaloric either by design or by spontaneous reduction of intake [8-12].

**Low carbohydrate diets and weight loss**

Data from various studies demonstrate that even a modest loss of 5–10% of initial body weight may significantly improve glycemic control, hyperinsulinemia and other metabolic abnormalities [13,14]. In the Diabetes Prevention Program (DPP) and the Finnish trials, lifestyle intervention including modest weight loss was effective in preventing the development of diabetes in a high risk population [15,16]. Weight control, per se, is thus a critical component for achieving glycemic control, improving insulin resistance and modifying CVD risk in patients with diabetes and insulin resistance as well as for diabetes prevention [14,17].

Traditionally, increased fat intake has been considered as the main cause for excess energy intake and obesity but the trends in food intake during the obesity epidemic do not support this notion [2,18]. While fat intake has decreased, carbohydrate intake has increased simultaneously. This rise in dietary intake of carbohydrates, and especially highly refined carbohydrate, is a likely culprit in promoting weight gain and obesity [19].

Weight change is governed by two factors: caloric balance and macronutrient composition. The first has general agreement and the expectation is that any hypocaloric diet, should be effective in achieving weight loss [20]. As noted above, LoCHO or VLCKD are frequently intentionally or spontaneously low calorie. The second consideration, macronutrient composition, is more controversial. Comparisons of isocaloric diets of different macronutrient composition frequently show no difference in effectiveness but there are several examples where distinct advantages accrue to one of the diets, usually the low carbohydrate arm [21-25].

In a recent study [21], for example, significantly greater weight loss was demonstrated with low carbohydrate intervention (< 10% calories from carbohydrates) despite higher caloric intake (1855 kcal/day) compared to high carbohydrate (60% calories from carbohydrates) with lower caloric intake (1562 kcal/day). There are several other reports indicating metabolic advantage in low carbohydrate diets over short term (3–6 months) [8,10,11,26-28]. Significant reductions in fat mass including truncal fat, which is a marker for visceral obesity, have been demonstrated in many studies [9,11,26,29]. A recent report [30] indicates that the effect will be seen primarily in subjects with insulin resistance. The association of insulin resistance with diabetes makes this of great importance.

Although the exact mechanism for this metabolic advantage is unknown, it is has been attributed to greater thermogenic effect of proteins in the face of increased demand for gluconeogenesis, increased futile cycling and increase in mitochondrial uncoupling [21,22,24]. Despite evidence suggesting more weight loss with isocaloric low carbohydrate diets, the issue of metabolic inefficiency with low carbohydrate dietary interventions is controversial and still not universally accepted.

The data for long term effectiveness of LoCHO diet is limited to studies with small sample size, poor adherence to dietary assignment in all dietary groups and inability to control the dietary carbohydrate amount over longer duration, making it difficult to demonstrate an appreciable difference between the dietary interventions. It is important to stress, however, that the same disclaimer must be made for low fat diets. Whereas calorie reduction by any means will lead to weight loss, the only comparisons of low fat diets are exactly the ones with low carbo-
hydrate diets and few researchers would maintain that low fat diets have great compliance or long term effects that can be attributed to the particular regimen [31]. Two of the low carbohydrate-low fat comparisons were continued for 1 year [8,27]. It is frequently cited that the difference in weight loss between the LoCHO diet and low fat diet was not statistically significant after one year but it should be pointed out that in these studies, participants had the freedom to increase the carbohydrate content of the diet over longer duration and it is reasonable to say that as carbohydrate is added back to the diet, its effectiveness wanes. For example, in the study by Foster et al. [8], there was no significant difference in the urinary ketone levels between the two study groups after 3 months, suggesting inadequate carbohydrate restriction during the later part of the study which would contribute to the similarity in various parameters between the groups. In addition, the authors of these studies included subjects who had dropped out of the study. This method, justified under the name "intention to treat analysis" obscures the information in the study and has the effect of making the more effective diet look worse. In another recent study [32] comparing the effects of four popular diets including LoCHO diet and low fat diet, there were no significant differences in weight loss in the different groups at the end of 1 year. However, this study also had the shortcomings of the above studies, including small sample size (40 subjects in each group) and poor adherence in all the groups (30–60% dropouts). The LoCHO diet group also failed to reach carbohydrate reduction goal with carbohydrate intake of 190 gm/day at 6 months and 12 months as compared to baseline of 239 gm/day. Hence, it is not surprising that weight loss was not significantly different in LoCHO diet group. What is encouraging is that despite such marginal carbohydrate restriction in the LoCHO group, this group was able to achieve a modest weight loss that was comparable to the other diet groups, while maintaining a greater improvement in lipid profile suggesting that even minimal carbohydrate restriction may have beneficial effects in term of weight loss and might be offered to those at high risk who fail to lose weight with traditional low fat diet.

**Low carbohydrate diet and glycemic control**

Diets containing 50–60% calories from carbohydrates have been the standard recommendation for patients with type 2 diabetes and metabolic syndrome [33-35]. However, evidence from several epidemiological studies such as the Nurses Health Study [36] and Health Professional Follow-Up Study [37] has linked dietary carbohydrate intake (measured as glycemic load) with risk of type 2 diabetes and CVD. In the Framingham Offspring Study [38], high glycemic index and glycemic loads were positively associated with metabolic syndrome. Prospective cohort studies have also linked carbohydrates with development of diabetes [39,40]. Compelling evidence from clinical and metabolic studies demonstrate worsening of glycemic control and dyslipidemia in diabetics with high carbohydrate diet [3,4,41,42] whereas low carbohydrate diet may reverse these serious metabolic abnormalities [10,27,43-46].

Carbohydrates are the major insulin secretagogues [47] and glycemic control in diabetic subjects is greatly influenced by dietary carbohydrate content. In fact, before the discovery of insulin, dietary carbohydrate restriction was the recommended treatment for diabetes management [48]. While subjects with type 1 diabetes are generally counseled to count dietary carbohydrates and adjust insulin dose accordingly [35], the concept of carbohydrate restriction in type 2 diabetes is not adequately emphasized. High carbohydrate intake is generally recommended, resulting in suboptimal glycemic control and lipoprotein profile, gradually increasing insulin and/or oral hypoglycemic medication requirement and weight gain. On the other hand, restriction of dietary carbohydrates is associated with improvement in glycemic control and other parameters of insulin resistance including body mass and lipid profile[8-10,43,45].

In the analysis of effects of macronutrient composition of diet on glycemic control, it is essential to differentiate the effect of carbohydrate restriction from that of weight loss so as to determine if the diet has beneficial effect on glycemic control independent of weight loss. This has been clarified by short term study in weight stable diabetic patients where carbohydrate restriction resulted in significant decrease (8.1% to 7.3%, p < 0.05) in glycosylated hemoglobin (HbA1c) compared to a high carbohydrate control diet [46]. In another study by the same group [45] in 8 diabetic men in a randomized 5-week cross over design with a 5-week wash out period, even larger beneficial effects on glycemic control were observed with low carbohydrate intervention (carbohydrate 20%, protein 30% and fat 50%) compared to control diet (carbohydrate 55%, protein 15% and fat 30%). The low carbohydrate diet had lower HbA1c (7.6 % ± 0.3), glucose levels and insulin levels compared to high carbohydrate group (HbA1c 9.8 % ± 0.5) despite similar weight loss with both diets. These data demonstrate that the benefits of low carbohydrate diet on glycemic control are independent of weight loss and are primarily due to carbohydrate reduction.

In a recent study [43] on obese diabetic subjects, a LoCHO diet (20% carbohydrates) was associated with a significant reduction in body weight, BMI, fasting blood glucose and HbA1C at 6 months compared to the high carbohydrate group (60% carbohydrates). Significant decreases in insulin and hypoglycemic medication requirement were
also observed in the low carbohydrate diet group. Similar improvements in glycemic control were also reported by Boden et al. [9]. The study of Samaha et al. [10] also reported a decrease in mean fasting plasma glucose (FPG) levels in diabetic subjects with low carbohydrate diet compared to low fat diet group. The decrease in FPG correlated with the weight loss in this study though the one year data did not show any significant difference, likely due to inability to achieve target carbohydrate intake in the LoCHO diet group and to the significant number of dropouts affecting the power of the study to measure a statistically significant difference.

To summarize, the effect of LoCHO diet on glycemic control was significantly greater and occurred independent of weight loss in those studies that were able to achieve and maintain adequate carbohydrate restriction. In other studies, the effect on glycemic control was modest and proportional to the weight loss, and at least comparable to that seen with low fat diet.

In conclusion, low carbohydrate diet is associated with significant improvement in glycemic control and has the potential for reduction in need for exogenous insulin or oral hypoglycemic medications. Increased monounsaturated fatty acid (MUFA) intake and reduction of saturated fat intake may further improve the insulin sensitivity and glycemic control with low carbohydrate diet.

**Low carbohydrate diet and postprandial hyperglycemia**

Postprandial hyperglycemia is a risk factor for CVD, particularly in diabetic patients [49-51]. Many studies including the Nurses Health Study [36] have suggested a link between dietary carbohydrates (measured in terms of glycemic load) and CVD risk. Furthermore, control of postprandial hyperglycemia has been shown to provide cardiovascular benefits, and to contribute to the overall decrease of hemoglobin A1c, something that has been clearly shown to reduce microvascular disease in both type 1 and type 2 diabetes [52,53]. Dietary carbohydrates are the major determinants of postprandial glucose levels [17,47,54] and LoCHO diets have been reported to lower postprandial glucose levels directly and indirectly by way of weight loss and may have beneficial effects on CVD risk factors [4,14]. Significant reductions in postprandial plasma glucose and plasma insulin levels with LoCHO diet have been demonstrated in many studies [4,9,42,55]. Furthermore, control of postprandial hyperglycemia with acarbose, an α-glucosidase inhibitor, has been demonstrated to significantly decrease the risk of diabetes in patients with impaired glucose tolerance [56,57].

**Low Carbohydrate diet and Dyslipidemia**

Type 2 diabetes and metabolic syndrome are commonly associated with atherogenic dyslipidemia, characterized by elevated triglycerides (TG) levels and low HDL levels [17,58]. Additionally, qualitative changes in LDL cholesterol may be present in the form of small, dense LDL particles which are more atherogenic and may be associated with higher risk of CVD [58-60]. Evidence from various studies has confirmed that LDL, HDL and triglycerides are independent predictors of CVD [17,61-63]. Since nearly 75 % of diabetics die of heart disease, control of diabetic dyslipidemia is an important strategy in the primary prevention of CVD and a low fat high carbohydrate diet has been the standard recommendation from various health organizations to achieve this target [33-35]. A mounting body of evidence however, has demonstrated that the traditional low fat high carbohydrate diet is associated with elevated triglyceride and low HDL cholesterol levels and may worsen the dyslipidemia of type 2 diabetes and metabolic syndrome [3,10,25,28]. Reduction in dietary intake of fat is frequently associated with increased intake of carbohydrates and leads to carbohydrate induced hypertriglyceridemia (HPTG) [64-69]. This phenomenon has been observed in subjects consuming high carbohydrate low fat diets for as few as 5 days, with replacement of as little as 10% fat with carbohydrate and with dietary fat intake of as much as 30% of energy [64,65]. Decreasing fat without increasing carbohydrate does not appear to elevate triglycerides, thereby suggesting that addition of carbohydrates and not reduction in fat is responsible for this HPTG seen with high carbohydrate low fat diets. Though the exact mechanism for carbohydrate induced HPTG has not been clearly elucidated, both increase in TG synthesis and decrease in fractional TG clearance have been demonstrated [64-66] with a possible contribution from increased hepatic de novo fatty acid synthesis [64,67]. A number of factors influence the occurrence of carbohydrate induced HPTG and these include high BMI (≥28 kg/ m²), insulin resistance, post menopausal state, and genetic factors [64,65]. Diabetic, insulin resistant and obese subjects are thus at even higher risk. In addition, type and form of carbohydrates, particularly high sugar/starch ratio also contribute to carbohydrate induced HPTG [64]. Conversely, LoCHO diets have been consistently demonstrated to lower triglycerides and increase HDL [8-11,26-28]. Even the studies which failed to show significant differences in weight loss between LoCHO diet and low fat diets after one year [8,27] demonstrated significant reduction in TG and an increase in HDL with the LoCHO diet despite inability of subjects to achieve target carbohydrate intake. This result suggests that the improvement in TG is not only independent of weight loss but, again, even modest reduction in carbohydrate intake may have significant benefits on lipids. Significant clinical implications comes from the VA-HIT study [61], where a
modest reduction in TG and elevation of HDL cholesterol were associated with notable improvement in CVD mortality.

Though weight loss per se, in combination with increased physical activity, is usually associated with an increase in HDL cholesterol and decreases in triglyceride and LDL cholesterol concentration, the beneficial effects on lipids of the caloric reduction in LoCHO diets appear to be secondary or additive to carbohydrate restriction and are seen even after adjusting for amount of weight loss[27].

A low fat diet, in the presence of weight loss is effective in lowering serum LDL cholesterol. On the other hand, such a regimen decreases HDL cholesterol without a significant increase in LDL size to less atherogenic form [70]. Emerging evidence suggests that LoCHO diets may actually have beneficial effects on LDL cholesterol by decreasing LDL particle concentration and increasing LDL size to less atherogenic form [25,28,70-73].

In summary, a low carbohydrate diet may be more effective than a low fat diet at improving the characteristic dyslipidemia associated with diabetes, namely high TG, low HDL and increased small dense LDL particles [70].

**Low carbohydrate diet and insulin resistance**

LoCHO diets have been reported to have beneficial effect on hyperinsulinemia seen in type 2 diabetes and insulin resistance [8-10,45]. The data is, however, limited by few studies with small number of diabetic subjects and differences in method of measuring insulin sensitivity in various studies. Boden et al. demonstrated significant improvement in insulin sensitivity, up to 75%, with a low carbohydrate diet as measured by euglycemic hyperinsulinemic clamp method [9]. In another study [29], significant decreases in insulin to glucose ratio were seen in the LoCHO group suggesting improved insulin sensitivity, especially in subjects with insulin resistance and higher baseline insulin levels. Similar improvement in insulin sensitivity was reported by Gannon, et al [45]. In the studies by Samaha et al. [10] and by Foster et al [8], carbohydrate restriction was associated with a significant increase in insulin sensitivity at 6 months (measured only in non-diabetic subjects) although the difference between the low fat and low carbohydrate groups was not statistically significant at 1 year [27]. Notably, again, these studies allowed increasing carbohydrate in the LoCHO group with time thereby reducing the effectiveness of this group. Reduction in visceral obesity and omental fat may be important since LoCHO diets have been reported to reduce fat mass including truncal fat over long term in many studies [11,21,26,29]. Finally, a recent study showed that effectiveness of low carbohydrate diets was more visible in a group that was insulin-resistant [30].

**Low carbohydrate diet and hypertension**

Hypertension is a common co-morbidity in type 2 diabetes affecting 20–60% of the diabetic population [74] and contributes significantly to CVD risk. Hypertension is a major predictor of increased macrovascular and microvascular complications of diabetes [17,52,53,75]. Hypertension in diabetes is usually a component of metabolic syndrome and is related to carotid wall atherosclerotic lesions and angina [17]. A number of studies in animals [76] and one in humans [77] have linked sugar intake with hypertension. Direct correlation between plasma insulin levels and blood pressure levels has been demonstrated and there is evidence to suggest a causal relationship between insulin resistance with resultant hyperinsulinemia and hypertension [17]. The proposed mechanisms include renal sodium retention, vascular smooth muscle proliferation, sympathetic stimulation and vascular hyperreactivity [17].

The role of macronutrient composition of diet on blood pressure has not been adequately studied, though any dietary intervention effective for improving insulin resistance should also have beneficial effects on hypertension. The relationship between hypertension and weight loss is well documented [13,74] and weight loss of 1 kilogram has been reported to decrease mean arterial blood pressure by approximately 1 mm Hg. Low carbohydrate diets have been reported to lower blood pressure by causing weight loss and improving the insulin sensitivity, though the magnitude of effect on blood pressure has been small (1–10 mm Hg) in most studies [8,10,29] and comparable to that seen with low fat diet.

**Low carbohydrate diet and inflammation**

Insulin resistance is the predominant mechanism associated with type 2 diabetes and is also central to the pathogenesis of metabolic syndrome [17]. Abnormal levels of inflammatory markers such as C-reactive protein and prothrombotic markers like plasminogen activator inhibitor-1 (PAI-1) have been reported in insulin resistant subjects [17] and may contribute to the increased CVD events in this population in combination with dyslipidemia and hypertension [17]. High carbohydrate diets, by increasing the insulin secretion, may worsen insulin resistance in diabetic patients and increase the inflammatory and prothrombotic tendencies in this patient population. The effect of low carbohydrate diet on various inflammatory and pro-coagulant markers is not well studied although these markers have been shown to improve with weight loss in general [13,78-80]. Therefore, any diet that causes effective weight loss should be able to cause a decrease in these inflammatory markers and such decreases in CRP [32,70] and PAI-1 levels [29] have been demonstrated with low carbohydrate diet. However, these data are limited, and long term studies are needed to confirm these
findings and to determine the impact of these parameters on the CVD end points with low carbohydrate diet.

The case for a low carbohydrate diet

Despite the growing popularity of LoCHO diets and emerging evidence for its effectiveness, there is reluctance among physicians to prescribe it, even in high risk populations who have failed to benefit from traditional low fat diets. The possible explanation is that although carbohydrate restriction can be implemented in any number of ways, it is generally identified with the popular Atkins diet for which health organizations have great hostility, focusing on a literal interpretation of permission for unlimited fat intake. Health organizations have been slow to adapt carbohydrate restricted diets even in the face clear evidence for the adverse effects of high carbohydrate intake exacerbating the metabolic abnormalities in diabetes and insulin resistant states. Similarly, we have previously pointed out the general tendency to downplay the beneficial effects of LoCHO diets by individual researchers. Weight loss associated with LoCHO diets has been continually attributed to alteration in body water. Numerous studies have shown that, although initial alteration in body water with carbohydrate restriction is possible, the new equilibrium state is achieved in 2–3 weeks, followed by active loss of fat mass. In fact, a recent study showed mean energy intake decreased from 3111 kcal/day to 2164 kcal/day on a low carbohydrate diet with mean energy deficit of 1027 kcal/day. The weight loss was proportional to mean energy deficit and was explained by loss of fat mass, not water loss.

Another concern that has been voiced is unlimited fat intake as part of low carbohydrate diet may cause weight gain and obesity over the long term. Whereas saturated fats have been linked with increased CVD risk, the use MUFA and PUFA have been inversely associated with CVD risk. Therefore, if carbohydrate restriction is used with increase in unsaturated fats, the benefits may be even more and indeed, improvement in glycemic control, insulin sensitivity and dyslipidemia including reduction in LDL cholesterol has been demonstrated with such dietary intervention in several clinical and metabolic studies.

Another major reason for lack of enthusiasm for LoCHO diet is misinterpretation of data provided by studies up to 1 year duration. The general view is that the LoCHO diet are not more effective than low fat high carbohydrate diet in terms of weight loss in studies up to 1 year duration despite impressive short term weight loss. However, as we mentioned earlier, considering that the data is already biased in favor of low fat diet, the lack of significance between the diet groups at 12 months still proves the superiority of LoCHO diet as it was able to achieve similar or better weight loss despite less than desired carbohydrate restriction. Again, even a marginal decrease in carbohydrate intake may be beneficial in terms of weight loss and lipid benefits. The overall dietary compliance was a major problem in all these studies but was generally comparable between the two diet groups. A lot has been said about nutritional inadequacy due to mineral, electrolytes and vitamin deficiencies and the adverse health effects of LoCHO diets on renal and skeletal mass. On the other hand, there is evidence that increasing sugar intake adds empty calories by displacement of whole foods and has been associated with a linear decrease in intake of many essential nutrients as demonstrated by Bogalusa Heart Study. Since carbohydrate restriction may limit some micronutrient and fiber intake, the popular versions of LoCHO diets recommend mandatory intake of multivitamins including calcium, fish oil and fiber supplements. The renal and skeletal effects remain theoretical concerns not substantiated with evidence. Studies up to 1 year have not shown any adverse effects on renal function or skeletal mass. Also, adequate intake of calcium and vitamin D supplements as routinely recommended with LoCHO diet should help preserve skeletal mass along with prescription of increased physical activity which should be offered to all irrespective of the dietary macronutrient composition. There have been some reports of increase blood urea nitrogen without any decrease in glomerular filtration which are related to increase in protein intake and do not represent renal insufficiency. A theoretically increased risk of renal stones has been claimed with LoCHO diet but again, there is no evidence for such claims and nothing that adequate hydration could not correct. However, in the absence of definite evidence, recommendations must be based on professional judgment. Although proponents of LoCHO diets recommend ad libitum fat intake, we do not endorse this and instead favor use of MUFA and PUFA which have been demonstrated in various studies to reduce the risk of CVD. A final irony is the report that physicians frequently choose LoCHO diets for themselves while recommending low fat for their patients.

Where we stand

Based on our examination of current evidence, we find concerns about LoCHO diets to be unsubstantiated and we see no problem in recommending them, at least as a means of caloric reduction. Of course, reducing calories by removing fat is universally agreed on as beneficial but the real question is which should be the priority. We believe from the evidence presented here that replacing fat with carbohydrate is deleterious and caloric restriction should be carried out by removing carbohydrate in prefer-
ence to removing fat. Although calorie counting is not recommended by various popular LoCHO diets, we routinely remind our patients to avoid excess calorie intake. Also, because restriction of carbohydrates may limit intake of certain vitamins and minerals, supplementation with multivitamin supplements including calcium is a usual recommendation with LoCHO diets. Since high fiber intake has been inversely associated with CVD [37,88], patients should be encouraged to increase fiber intake and should receive fiber supplements if necessary.

As for VLCKD where carbohydrate restriction is targeted to 20–30 gm/day at least for two weeks, we consider this an extreme change for most people and therefore we would not recommend it without substantial evidence from clinical trials is provided as to the benefits of this extreme dietary intervention.

Low Carbohydrate diet and the current guidelines for diabetes management

Traditionally, a low fat high carbohydrate diet containing 55–70 % carbohydrates, 15–20% proteins and 20–30% fats has been recommended by various health organizations [33-35] for subjects at high risk of CVD including those with diabetes and metabolic syndrome. Despite accumulating evidence suggesting deleterious effects of high carbohydrate diet and potential benefits of carbohydrate restriction, LoCHO diet have met with increased resistance and have not been accorded its deserved place in various treatment guidelines.

The current position statement of the American Diabetes Association (ADA), however, recognizes the importance of amount of dietary carbohydrates: "With regard to the glycemic effects of carbohydrates, the total amount of carbohydrate in meals or snacks is more important than the source or the type". This organization also agrees with role of carbohydrate restriction as stated "In weight maintaining diets for type 2 diabetes, replacing carbohydrates with monounsaturated fats reduces post prandial glycemia and triglyceridemia" and recommends that "carbohydrates and monounsaturated fat together should provide 60–70% of the energy intake and the relative contributions of carbohydrate and monounsaturated fats to energy intake should be individualized". This can be considered as a nod of approval for carbohydrate restriction though no specific recommendation has been made. Furthermore, the ADA's recommendation of individualization according to patient's risk may provide the much needed flexibility for adjusting the carbohydrate content according to the patient's requirement [47]. This gradual adoption of carbohydrate restriction is also reflected by a recent statement from ADA limiting dietary carbohydrate intake to provide 45–65% of the calories [47] which is less than previously recommended.

Conclusion

Low carbohydrate diet compares more favorably, at least over the short term, to traditional low fat for improving glycemic control, insulin sensitivity and dyslipidemia of diabetes with reduction in triglycerides, increase in HDL cholesterol and modification of LDL to less atherogenic form. The need of the hour is to accept the benefits of carbohydrate restriction with reservation and to establish guidelines for its use, especially emphasizing use of mono and polyunsaturated fats as the way to achieve caloric balance since these have been inversely linked with CVD risk in various studies. In the mean time, clinical trials need to be conducted using graded levels of carbohydrate restriction and fat intake, with special emphasis on unsaturated fats, to examine their effects of on weight loss, glycemic control, insulin resistance and CVD risk. This is to resolve the present controversy about optimal dietary option for patients with diabetes.

Competing interests

The author(s) declare that they have no competing interests.

Authors' contributions

SA conducted literature search, prepared the manuscript and helped in presentation of final draft, SIM conceived the idea, organized the contents and helped in the preparation and presentation of final manuscript.

References

1. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP: The continuing epidemics of obesity and diabetes in the United States. JAMA 2001, 284:195-1200.
2. Kennedy ET, Bowman SA, Powell R: Dietary-fat intake in the US population. J Am Coll Nutr 1999, 18:207-212.
3. Garg A, Grundy SM, Unger RH: Comparison of effects of high and low carbohydrate diets on plasma lipoproteins and insulin sensitivity in patients with mild NIDDM. Diabetes 1992, 41:1278-1285.
4. Garg A, Bantle JP, Henry RR, Coughlin AM, Griner KA, Raatz SK, Brinkley L, Chen YD, Grundy SM, Huet BA, et al.: Effects of varying carbohydrate content of diet in patients with non-insulin-dependent diabetes mellitus. JAMA 1994, 271:1421-1428.
5. Atkins RC: Dr. Atkins New Diet Revolution. New York, Avon Books; 2002.
6. Agatston AS: The South Beach Diet. New York, Random House; 2003.
7. Eades MR, Eades MD: Protein Power. New York, Bantam Books; 1996.
8. Boden G, Sargrad K, Homko C, Mozoli M., TPS: Effect of a Low-carbohydrate Diet on Appetite, Blood Glucose Levels, and Insulin Resistance in Obese Patients with Type 2 Diabetes. Ann Intern Med 2005, 142:403-411.
9. Larossa JC, Fry AG, Muesing R, Rosing DR: Effects of high-protein, low-carbohydrate dieting on plasma lipoproteins and body weight. J Am Diet Assoc 1980, 77:264-270.
10. Foster GD, Wyatt HR, Hill JO, McGuckin BG, Brill C, Mohammed BS, Szapary PO, Rader DJ, Edman JS, Klein S: A randomized trial of a low-carbohydrate diet for obesity. N Engl J Med 2003, 348:2082-2090.
11. Samaha FF, Iqbal N, Shashtad P, Chican KL, Dally DA, McGory J, Williams T, Williams M, Gracyl Ej, Stern L: A low-carbohydrate as compared with a low-fat diet in severe obesity. N Engl J Med 2003, 348:2074-2081.
12. Yancy WSJ, Olsen MK, Guyton JR, Bakst RP, Westman EC: A low- carbohydrate, ketogenic diet versus a low-fat diet to treat obesity and type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2004, 140:769-777.

13. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults—The Evidence Report. National Institutes of Health. Obes Res 1998, 6 Suppl 5:S209-31.

14. McFarlane SI, Shin JJ, Rundek T, Bigger JT: Prevention of type 2 diabetes. Curr Diab Rep 2003, 3:235-241.

15. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403.

16. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas P, Salminen V, Uusitupa M: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001, 344:1343-1350.

17. McFarlane SI, Banerji M, Sowers JR: Nutrition & Metabolism: Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults—The Evidence Report. National Institutes of Health. Obes Res 1998, 6 Suppl 5:S209-31.

18. Mokdad AH, Serdula MK, Dietz WH, Bowman BA, Marks JS, Koplan JP: A comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and body composition in overweight men and women. Am J Clin Nutr 2000, 71:15-25.

19. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001, 344:1343-1350.

20. Freedman RD, Fine EJ: Cardiovascular disease: a summary for health professionals. Nutr Metab (Lond) 2004, 1:15.

21. Feinman RD, Sharman M, Gomez A, Judelson D, Rubin M, Watson G, Sowers JR: The national cholesterol education program adult treatment panel III guidelines versus conventional weight loss diets in severely obese women. Am J Clin Nutr 2004, 79 Suppl 1:405-Supp.

22. Fine EJ, Feinman RD: Thermodynamics of weight loss diets. Nutr Metab (Lond) 2004, 1:15.

23. Feinman RD, Fine EJ: The law of thermodynamics. Nutr J 2004, 3:9.

24. Feinman RD, Fine EJ: The thermodynamics and metabolic advantage of weight loss diets. Metabolic Syndrome and Related Disorders 2003, 1:209-219.

25. Westman EC, Mavropoulos J, Yancy WS, Volek JS: A review of low-carbohydrate ketogenic diets. Curr Atheroscler Rep 2003, 5:476-483.

26. Brehm BJ, Seeley RJ, Daniels SR, D’Alessio DA: A randomized trial comparing a very low-carbohydrate diet and a calorie-restricted low-fat diet in healthy women. J Clin Endocrinol Metab 2003, 88:1617-1623.

27. Stern L, Igbal N, Seshadri P, Chicozo KL, Daily DA, McGrory J, Williams M, Gracely EJ, Samaha FF: The effects of low-carbohydrate versus conventional weight loss diets in severely obese adults: one-year follow-up of a randomized trial. Ann Intern Med 2004, 140:778-785.

28. Aude YW, Agatston AS, Lopez-Jimenez F, Lieberman EH, Marie A, Jensen MC, Aikhanov M, Peterson CM: Utility of a short-term 25% carbohydrate diet on improving glycemic control in type 2 diabetes mellitus. J Am Coll Nutr 1998, 17:595-600.

29. Nielsen JV, Jonasson E, Nilsen AK: Lasting improvement of hyperglycaemia and bodyweight: low-carbohydrate diet in type 2 diabetes—a brief report. Ups J Med Sci 2005, 110:69-73.

30. Boden G, Bergman RN, Birkenkamp-Dieck G, Zander V, Salenius S, Kulkarni K, Geil P, Dietz WH: Effect of a low-carbohydrate diet on appetite, blood glucose levels, and insulin resistance in patients with type 2 diabetes. Ann Intern Med 2005, 142:403-411.

31. Gannon MC, Nuttall FQ: Effect of a high-protein, low-carbohydrate diet on blood glucose control in people with type 2 diabetes. Diabetes Care 2004, 53:2375-2382.

32. Gannon MC, Nuttall FQ, Saeed A, Jordan K, Hoover H: An increase in dietary protein improves the blood glucose response in persons with type 2 diabetes. Am J Clin Nutr 2003, 78:734-741.

33. Bandi RM, Eckel RH, Wagenknecht LE, Daniels SR, Deckelbaum RJ, Erman JW, Kris-Etherton P, Goldberg JF, Kotchen TA, Lichtenstein AH, Mitch WE, Mullins R, Robinson K, Wylie-Rosett J, St Jeor S, Sutjue T, Tribble DL, Bazzarre TL: AHA Dietary Guidelines: revision 2000: A statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Circulation 2000, 102:2284-2299.

34. Frantz MJ, Bantle JP, Beebe CA, Brunzell JD, Chisson JL, Garg A, Holzmeister LA, Hoogwerf B, Mayer-Davis E, Moreland AD, Purnell JQ, Wheeler M: Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diabetes Care 2002, 25:148-198.

35. Liu S, Willcutt WC, Stannard MJ, Hu FB, Franz M, Sampson L, Hennekens CH, Manson JE: A prospective study of dietary glycemic load, carbohydrate intake, and risk of coronary heart disease in US women. Am J Clin Nutr 2000, 71:785-792.

36. Hu FB, Willcutt WC: Diet and coronary heart disease: findings from the Nurses’ Health Study and Health Professionals’ Follow-up Study. J Nutr Health Aging 2001, 5:132-138.

37. McKeown NM, Mgs JB, Liu S, Saltzman E, Wilson PW, Jacques PF: Carbohydrate nutrition, insulin resistance, and the prevalence of the metabolic syndrome in the Framingham Offspring Cohort. Diabetes Care 2004, 27:538-546.

38. Salmeron J, Ascherio A, Rimm EB, Colditz GA, Willett WC, Stampfer MJ, Dietary fiber, glycemic load, and risk of NIDDM in men. Diabetes Care 1997, 20:545-550.

39. Salmeron J, Manspe JC, Stampfer MJ, Cook D, Willett WC: Dietary fiber, glycemic load, and risk of non-insulin-dependent diabetes mellitus in women. JAMA 1997, 277:472-477.

40. Garg A, Bonanome A, Grundy SM, Zhang ZJ, Unger RH: Comparison of a high-carbohydrate diet with a high-monounsaturated-fat diet in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1998, 319:829-834.

41. G Wonderful E, Mikhalevich M, Volek JS, Bistrian B, Nelson DH, Petersen CM: Insulin resistance and cardiovascular disease: a statement by the American Diabetes Association. Diabetes Care 2003, 26:277-289.

42. Blondo M, Morgan JB, Dickerson JW: Dietary advice in the management of diabetes mellitus—history and current practice. JR Soc Med 1997, 11:171-175.

43. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology Collaborative Analysis Of Diagnostic criteria in Europe. Lancet 1999, 354:617-621.

44. Hufniedel M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmehel H, Ziegelschel HJ, Lindner J: Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996, 39:1577-1583.

45. Levit EV, Song Y, Ford ES, Liu S: Is nondiabetic hyperglycaemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med 2004, 164:2147-2155.
51. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993, 329:977-986.

52. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352:837-853.

53. Jenkins DJ, Wolever TM, Jenkins AL, Josse RG, Wong GS: The glycemic response to carbohydrate foods. Lancet 1984, 2:388-391.

54. Wolever TM, Mehling C: Long-term effect of varying the source or amount of dietary carbohydrate on postprandial plasma glucose, insulin, triacylglycerol, and free fatty acid concentrations in subjects with impaired glucose tolerance. Am J Clin Nutr 2001, 74:959-965.

55. Chiasson JL, Gomis R, Hanefeld M, Josse RG, Karasik A, Laakso M: The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus. Diabetes Care 1998, 21:1720-1725.

56. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002, 359:2072-2077.

57. Haffner SM: Management of dyslipidemia in adults with diabetes. Diabetes Care 1998, 21:160-178.

58. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willcott WC, Krauss RM: Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1998, 280:1917-1921.

59. Griffin BA, Freeman DJ, Tait GW, Thomson J, Calske MJ, Packard CJ, Shepherd J: Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis 1994, 106:241-253.

60. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faa FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wiss T: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999, 341:410-418.

61. Collins R, Armitage J, Parish S, Sleight P, Peto R, MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003, 361:2005-2016.

62. Turner RC, Mills H, Neil HA, Stratton IM, Manley SE, Matthews DR, Holman RR: Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS 23). BMJ 1998, 316:823-828.

63. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment Of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285:2485-2497.

64. Parks EJ, Hellerstein MK: Carbohydrate-induced hypertriglyceridemia: historical perspective and review of biological mechanisms. Am J Clin Nutr 2000, 71:412-433.

65. Parks EJ: Effect of dietary carbohydrate on triglyceride metabolism in humans. J Nutr 2001, 131:S277S-2774S.

66. Hudgins LC: Effect of high-carbohydrate feeding on triglyceride and saturated fatty acid synthesis. Proc Soc Exp Biol Med 2000, 225:178-183.

67. Schwarz JM, Linfoot P, Dare D, Aghajanian K: Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets. Am J Clin Nutr 2003, 77:43-50.

68. Saris WH: Sugars, energy metabolism, and body weight control. Am J Clin Nutr 2003, 78:8505-857S.

69. Fried SK, Rao SP: Sugars, hypertriglyceridemia, and cardiovascular disease. Am J Clin Nutr 2003, 78:873S-880S.

70. Seshadri P, Iqbal N, Stern L, Williams M, Chicano KL, Daly DA, McGorry J, Gracey EJ, Rader DJ, Samaha FF: A randomized study comparing the effects of a low-carbohydrate diet and a conventional diet on lipoprotein subfractions and C-reactive protein levels in patients with severe obesity. Am J Med 2004, 117:398-405.

71. Volek JS, Westman EC: Very-low-carbohydrate weight-loss diets revisited. Cleve Clin J Med 2002, 69:849, 853, 856-8 passim.

72. Hickey JT, Hickey L, Yancy WS, Juana H, C.Westman E: Clinical use of a carbohydrate-restricted diet to treat the dyslipidemia of the metabolic syndrome. Metabolic syndrome and related disorders 2003, 1:227-232.

73. Yancy WS, Vernon MC, Westman EC: A pilot trial of low carbohydrate ketogenic diet in patients with type 2 diabetes. Metabolic syndrome and related disorders 2003, 1:239-243.

74. Arauz-Pacheco C, Parrott MA, Raskin P: The treatment of hypertension in adult patients with diabetes. Diabetes Care 2002, 25:134-147.

75. El-Ataz F, McFarlane SI, Sowers JR: Diabetes, hypertension, and cardiovascular derangements: pathophysiology and management. Curr Hypertens Rep 2004, 6:215-223.

76. Preuss HG, Zein M, MacArthy P, Dipette D, Sabnis S, Knapka J: Sugar-induced blood pressure elevations over the lifespan of three substrains of Wistar rats. J Am Coll Nutr 1998, 17:36-47.

77. Fishman WM: Metabolism of sugar and physical performance. Am J Clin Nutr 1995, 62:2285-241S.

78. Klein S, Sheard NF, Pi-Sunyer X, Daly A, Wylie-Rosett J, Kulkarni K, Clark NG: Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition. Diabetes Care 2004, 27:2067-2073.

79. Tchernof A, Nolan A, Sites CK, Ades PA, Poehlman ET: Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation 2002, 105:564-569.

80. Ziccardi P, Nappo F, Giugliano G, Esposito K, Marfella R, Ciolfi M, D’Andrea F, Molinari AM, Giugliano D: Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 2002, 105:804-809.

81. Arora S, McFarlane SI: Review on "Atkins Diabetes Revolution: The Groundbreaking Approach to Preventing and Controlling Type 2 Diabetes" by Mary C. Vernon and Jacqueline A. Eberstein. Nutr Metab (Lond) 2004, 1:114.

82. A critique of low-carbohydrate ketogenic weight reduction regimens. A review of Dr. Atkins’ diet revolution. Jama 1973, 21: 1415-1419.

83. Fisher JS, Drenick EJ: Starvation and semistarvation diets in the management of obesity. Am J Clin Nutr 1987, 46:485-484.

84. Hu FB, Manson JE, Willcott WC: Types of dietary fat and risk of coronary heart disease: a critical review. J Am Coll Nutr 2001, 20:5-19.

85. Mensink RP, Katan MB: Effect of dietary fatty acids on serum lipids and lipoproteins. A meta-analysis of 27 trials. Arterioscler Thromb 1992, 12:911-919.

86. Farris RP, Nicklas TA, Myers L, Benerson GS: Nutrient intake and food group consumption of 10-year-olds by sugar intake level: the Bogalusa Heart Study. J Am Coll Nutr 1998, 17:579-585.

87. La Puma J, Szapary P, Maki KC: Physicians recommendations for and personal use of low-fat and low-carbohydrate diets. Int J Obes Relat Metab Disord 2005, 29:251-253.

88. Hu FB, Willcott WC: Optimal diets for prevention of coronary heart disease. JAMA 2002, 288:2569-2578.